AstraZeneca (LON:AZN) Receives “Sell” Rating from Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “sell” rating reissued by research analysts at Deutsche Bank Aktiengesellschaft in a research report issued on Wednesday,Digital Look reports. They presently have a £115 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s target price indicates a potential downside of 2.88% from the company’s current price.

Other equities research analysts have also issued reports about the stock. Berenberg Bank reaffirmed a “buy” rating and issued a £160 price objective on shares of AstraZeneca in a research note on Tuesday, July 28th. Jefferies Financial Group reissued a “buy” rating and set a £175 target price on shares of AstraZeneca in a research note on Monday, August 3rd. Finally, Citigroup boosted their target price on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a report on Tuesday, July 28th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of £152.17.

AstraZeneca Stock Performance

Shares of AZN stock opened at £118.41 on Wednesday. The stock has a market capitalization of £183.65 billion, a PE ratio of 17.73, a PEG ratio of 0.86 and a beta of 0.21. The business’s 50 day simple moving average is £129.43 and its 200 day simple moving average is £138.52. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59. AstraZeneca has a one year low of £107.84 and a one year high of £157.32.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.